Specific Biologics Raises $35M Series A for ALS Gene Editing

The size of a gene editor becomes part of the medicine's development plan before a patient ever receives it. Specific Biologics has designed its lead ALS approach around an editor small enough for a single viral delivery vehicle, putting the practical work of reaching cells alongside the work of changing their DNA.

The Toronto company closed an oversubscribed US$35M Series A on November 2, 2026, led by Hatteras Venture Partners. Returning investors Lumira Ventures and adMare BioInnovations joined Genesys Capital, BDC's Life Sciences Venture Fund, DeepWork Capital and Seido Capital. The stated objective is to carry its lead Dualase candidate through initial clinical biomarker proof of concept in the first cohort of an adaptive Phase I/II trial for C9ORF72-associated amyotrophic lateral sclerosis.

That is a specific assignment for a platform company: move a particular genetic intervention toward evidence in a defined patient population. Co-founder and CEO Brent Stead and CSO Brad Geddes are taking a technology rooted in university research into that clinical-development task, while the evidence disclosed so far remains preclinical.

Why the delivery package belongs in the financing story

Specific Biologics' Dualase platform uses two cutting sites to influence how cells repair DNA. Its sequence-removal approach places cuts around an unwanted stretch, with the design intended to join the remaining ends precisely. The relevant target in the lead ALS program is an expanded DNA repeat in the C9ORF72 gene, which the company aims to shorten while preserving the surrounding sequences needed for normal biological function.

The company says the editor and guides can fit inside one adeno-associated virus, or AAV, for delivery to the central nervous system. Its platform materials connect that packaging to manufacturing and dosing. From an operating perspective, those relationships matter because a development team has to make the delivery system and editor work together; precision on a diagram still leaves a substantial medicine-development assignment.

Specific reports repeat reduction in patient-derived ALS cells and disease-relevant animal models, including no detectable off-target effects under the conditions tested. Those are company-reported preclinical findings. Human safety, the durability of any effect and benefit to patients require clinical investigation, and the funding announcement does not establish that a trial has begun or that a patient has been enrolled.

The investors have been following a long research relationship

Brent Stead's path back to Western University helps explain how Specific Biologics reached this round. In Western's account of the company's origins, Stead returned in 2017 to David Edgell, the biochemistry professor who had been an examiner on his doctoral work. After working in industry, Stead wanted to turn the laboratory's dual-cleaving nuclease research into potential medicines. He joined Edgell's laboratory on a research contract as the technology moved toward an investable company.

Lumira Ventures and adMare backed Specific's first institutional financing in December 2021, then disclosed renewed investment in October 2023. Those earlier announcements describe the work of developing and testing a platform across disease-relevant targets. Their participation in the Series A carries that financing relationship into a more focused clinical objective, with Hatteras now leading the syndicate.

The investment logic has therefore had time to acquire history. Returning investors can assess the program against the work they previously financed, while a new lead brings another institution into responsibility for its development. That continuity is meaningful without inventing a valuation, an exit plan or a lifetime funding total: prior investment amounts are not disclosed in those announcements, and the new US$35M should stand on its own.

A defined genetic population changes the evidence conversation

Specific's lead program addresses C9ORF72-associated ALS, giving the development effort a particular genetic target within a devastating disease. The company describes an intended adaptive Phase I/II study with an early clinical biomarker objective. A biomarker result would be one part of understanding whether the intervention is doing useful biological work, alongside the clinical assessment required to understand safety and patient outcomes.

The distinction among genetic populations matters. The FDA's Qalsody record describes tofersen for adults with SOD1-associated ALS, a different genetic form. Specific's announcement should therefore be read in the context of its C9ORF72 target, rather than expanded into a claim that ALS has no approved treatments. Nor does another program's regulatory history establish a route or outcome for Dualase.

For the investors, the attraction is the opportunity to learn something consequential about a precisely defined intervention. For the clinical team, that opportunity arrives as a set of practical decisions about a candidate, delivery and a first cohort. The announcement supplies a financing objective, while leaving the trial's start date, sites, enrollment and readout schedule undisclosed. Keeping those details separate from the capital event gives readers a useful record to return to as the program develops.

Platform breadth will keep competing for attention

Specific's development pipeline extends beyond the lead neurological application. The company describes cystic fibrosis work using a lipid nanoparticle formulation, liver-directed research and discovery opportunities across several tissues. These are different development assignments, with delivery approaches and genetic targets that should remain distinct in any account of the platform's progress.

That breadth creates an organizational choice. A platform can offer many plausible programs while a financing round needs a tractable objective, and Specific has made the lead ALS candidate's initial clinical biomarker evidence central to this announcement. The broader research can continue to inform the business, but the Series A's disclosed purpose gives investors and prospective partners a common point around which to follow the company's next disclosures.

DevCuration's coverage of Setara's rare-disease drug studies and Dren Bio's private financing offers other examples of capital being attached to specific stages of medicine development. Specific's assignment begins with its own delivery design, genetic population and academic lineage. As Brent Stead and Brad Geddes bring that work toward a first clinical cohort, the research relationships behind Dualase will have to support decisions that reach beyond the laboratory.